Multiple Myeloma: What Managed
Care Needs To Know
Post Test

A score of 70% must be achieved to receive continuing education credits.
1. Which of the following symptoms is seen in the highest number of multiple myeloma patients:
  a. Bone pain
  b. Fatigue/weakness
 c. Anemia
2. Which of the following is true for both Monoclonal gammopathy of unknown significance (MGUS) and Smoldering multipe myeloma:
  a. M protein less than 3 g/dl
  b. Greater than 10% plasma cells in bone marrow
 c. No end-organ damage
3. What factors determine whether or not a symptomatic Myeloma patient is a candidate for transplant?
 a. Age
 b. Comorbid conditions
 c. Performance status
 d. All of the above
4. Which of the following is a primary therapy for non-transplant myeloma candidates?
 a. Lenalidomide
 b. Bortezomib
 c. Thalidomide
5. Allogenic transplant avoids contamination of reinfused tumor cells.
 True
 False
6. In some patients, an effective way to treat a relapse of Multiple Myeloma is to recycle an old treatment regimen.
 True
  False
7. What percentage of Multiple Myeloma patients develop bony manifestations?
  a. 30%
 b. 50%
 c. 85%
8. Treatment of Multiple Myeloma can include new therapeutic agents, transplant, and/or maintenance, and may also include the treatment of complications and/or side effects.
 True
  False
9. Multiple Myeloma is the result of a stepwise progression from MGUS.
   True
   False
10. For one year of treatment, which of the following is the most expensive therapy currently available for Multiple Myeloma:
  a. Autologous Stem Cell Transplant (SCT)
  b. SCT inpatient
 c. Thalidomide
 d. Lenalidomide
 e. Bortezomib
 

 
Multiple Myeloma: What Managed
Care Needs To Know

Activity evaluation and improvement process:
Please rate this activity on the following scale:
4 - Excellent        3 - Good        2 - Fair        1 - Poor
1.Based on the content presented I am better able to:  
  • Understand the diagnosis of Multiple Myeloma (MM)
    4        3        2        1
  • Identify treatment options as defined in the International Staging System
    4        3        2        1
  • Review National Comprehensive Cancer Network practice guidelines for MM
    4        3        2        1
  • Describe complications in the treatment of MM and methods to overcome
    4        3        2        1
2. Activity met my expectations    4        3        2        1  
3. Activity was free of bias    4        3        2        1
4. Activity content was understandable    4        3        2        1
5. Presenter was free of bias    4        3        2        1
6. Method of learning was beneficial    4        3        2        1
7. Presenter covered material to extent expected    4        3        2        1
8. Comments: 
9. What other topics are of interest to you?


Due to the content of this activity, I will change my practice patterns by:

Educate appropriate member populations on Multiple Myeloma
Provide education to providers about Multiple Myeloma
Make sure my organization is providing access to treatment guidelines such as NCCN
My practice patterns will not change
Other    Specify:

Continuing education implies quality improvement in behavior. As part of our quality improvement process, NAMCP/AAMCN will contact you 1 month from your post test submission to monitor change.
Name:  
Profession: MD  DO  RN  LPN  Other
Company:  
Mailing Address:  
City, State, Zip:  
Phone:  
Fax:  
Email:  
Heard About Activity By: eNews  Colleague  Internet    JMCM Article
 Email   Phone
 
Send my certificate by: U.S. Mail             Email
 

Help us cut down spam.

Type the number 411 into
the following box (Required)